Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.35 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 2/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211780 | 1.00 | DGAT1 (0.40) | DGAT1MTORRPTORMLST8CHEK1 | |
| SCHEMBL2723620 | 0.91 | DGAT1 (0.43) | DGAT1MTORRPTORMLST8CHEK1 | |
| SCHEMBL10277588 | 0.91 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL10277722 | 0.90 | DGAT1 (0.39) | DGAT1GPR119 | |
| SCHEMBL6890836 | 0.90 | DGAT1 (0.39) | DGAT1GPR119 | |
| SCHEMBL10237593 | 0.90 | DGAT1 (0.40) | DGAT1MTORRPTORMLST8ACACB | |
| SCHEMBL7878601 | 0.90 | DGAT1 (0.40) | DGAT1MTORRPTORMLST8ACACB | |
| SCHEMBL30913 | 0.90 | GPR119 (0.42) | DGAT1GPR119ALDH1A1HPGDTSHR | |
| SCHEMBL2723694 | 0.89 | DGAT1 (0.41) | DGAT1MTORRPTORMLST8CHEK1 | |
| SCHEMBL2679713 | 0.88 | DGAT1 (0.36) | DGAT1CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8609675-B2 | Fused Tricyclic Compounds as novel mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | DGAT1 3898/4885MTOR 1/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.